Cost-effectiveness of adjuvant docetaxel for node-positive breast cancer patients: results of the PACS 01 economic study
Author:
Publisher
Elsevier BV
Subject
Oncology,Hematology
Link
http://academic.oup.com/annonc/article-pdf/21/7/1448/390716/mdp561.pdf
Reference27 articles.
1. Epidemiology and nongenetic causes of breast cancer;Willett,2000
2. Epirubicin increases long-term survival in adjuvant chemotherapy of patients with poor-prognosis, node-positive, early breast cancer: 10-year follow-up results of the French Adjuvant Study Group 05 randomized trial;Bonneterre;J Clin Oncol,2005
3. Docetaxel is a major cytotoxic drug for the treatment of advanced breast cancer: a phase II trial of the Clinical Screening Cooperative Group of the European Organization for Research and Treatment of Cancer;Chevallier;J Clin Oncol,1995
4. Phase II trial of docetaxel in advanced anthracycline-resistant or anthracenedione-resistant breast cancer;Ravdin;J Clin Oncol,1995
5. Phase II trial of docetaxel: a new, highly effective antineoplastic agent in the management of patients with anthracycline-resistant metastatic breast cancer;Valero;J Clin Oncol,1995
Cited by 13 articles. 订阅此论文施引文献 订阅此论文施引文献，注册后可以免费订阅5篇论文的施引文献，订阅后可以查看论文全部施引文献
1. Pathologic response at the epicenter of the treatment decision-making process in Human Epidermal Receptor–Type 2 overexpressing (Her2+) Early Breast Cancer (EBC): Challenges and opportunities for financially-constrained healthcare systems;The Breast;2020-12
2. Taxanes for adjuvant treatment of early breast cancer;Cochrane Database of Systematic Reviews;2019-09-02
3. Cost–utility analyses of drug therapies in breast cancer: a systematic review;Breast Cancer Research and Treatment;2016-08-30
4. European cost-effectiveness study of uPA/PAI-1 biomarkers to guide adjuvant chemotherapy decisions in breast cancer;European Journal of Cancer;2016-08
5. Cost-Effectiveness of Chemotherapy for Breast Cancer and Age Effect in Older Women;Value in Health;2015-12
1.学者识别学者识别
2.学术分析学术分析
3.人才评估人才评估
"同舟云学术"是以全球学者为主线，采集、加工和组织学术论文而形成的新型学术文献查询和分析系统，可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容，当前同舟云学术共收录了国内外主流学术期刊6万余种，收集的期刊论文及会议论文总量共计约1.5亿篇，并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询！咨询电话：010-8811{复制后删除}0370
www.globalauthorid.com
TOP
Copyright © 2019-2024 北京同舟云网络信息技术有限公司 京公网安备11010802033243号 京ICP备18003416号-3